182 related articles for article (PubMed ID: 36018850)
1. S146L in MYC is a context-dependent activating substitution in cancer development.
Hinds JW; Feris EJ; Wilkins OM; Deary LT; Wang X; Cole MD
PLoS One; 2022; 17(8):e0272771. PubMed ID: 36018850
[TBL] [Abstract][Full Text] [Related]
2. The Cellular Protein Complex Associated with a Transforming Region of E1A Contains c-MYC.
Vijayalingam S; Subramanian T; Zhao LJ; Chinnadurai G
J Virol; 2016 Jan; 90(2):1070-9. PubMed ID: 26559831
[TBL] [Abstract][Full Text] [Related]
3. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.
D'Cruz CM; Gunther EJ; Boxer RB; Hartman JL; Sintasath L; Moody SE; Cox JD; Ha SI; Belka GK; Golant A; Cardiff RD; Chodosh LA
Nat Med; 2001 Feb; 7(2):235-9. PubMed ID: 11175856
[TBL] [Abstract][Full Text] [Related]
4. Formation of a structurally-stable conformation by the intrinsically disordered MYC:TRRAP complex.
Feris EJ; Hinds JW; Cole MD
PLoS One; 2019; 14(12):e0225784. PubMed ID: 31790487
[TBL] [Abstract][Full Text] [Related]
5. MYC interacts with the human STAGA coactivator complex via multivalent contacts with the GCN5 and TRRAP subunits.
Zhang N; Ichikawa W; Faiola F; Lo SY; Liu X; Martinez E
Biochim Biophys Acta; 2014 May; 1839(5):395-405. PubMed ID: 24705139
[TBL] [Abstract][Full Text] [Related]
6. c-Myc transformation domain recruits the human STAGA complex and requires TRRAP and GCN5 acetylase activity for transcription activation.
Liu X; Tesfai J; Evrard YA; Dent SY; Martinez E
J Biol Chem; 2003 May; 278(22):20405-12. PubMed ID: 12660246
[TBL] [Abstract][Full Text] [Related]
7. Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age.
Thng DKH; Toh TB; Chow EK
Trends Pharmacol Sci; 2021 Mar; 42(3):166-182. PubMed ID: 33422376
[TBL] [Abstract][Full Text] [Related]
8. TRRAP-dependent and TRRAP-independent transcriptional activation by Myc family oncoproteins.
Nikiforov MA; Chandriani S; Park J; Kotenko I; Matheos D; Johnsson A; McMahon SB; Cole MD
Mol Cell Biol; 2002 Jul; 22(14):5054-63. PubMed ID: 12077335
[TBL] [Abstract][Full Text] [Related]
9. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain.
Hoang AT; Lutterbach B; Lewis BC; Yano T; Chou TY; Barrett JF; Raffeld M; Hann SR; Dang CV
Mol Cell Biol; 1995 Aug; 15(8):4031-42. PubMed ID: 7623799
[TBL] [Abstract][Full Text] [Related]
10. E2F transcriptional activation requires TRRAP and GCN5 cofactors.
Lang SE; McMahon SB; Cole MD; Hearing P
J Biol Chem; 2001 Aug; 276(35):32627-34. PubMed ID: 11418595
[TBL] [Abstract][Full Text] [Related]
11. Attacking c-Myc: targeted and combined therapies for cancer.
Huang H; Weng H; Zhou H; Qu L
Curr Pharm Des; 2014; 20(42):6543-54. PubMed ID: 25341931
[TBL] [Abstract][Full Text] [Related]
12. Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target in Cancers.
Vízkeleti L; Spisák S
Cells; 2023 Jun; 12(13):. PubMed ID: 37443779
[TBL] [Abstract][Full Text] [Related]
13. HAUSP regulates c-MYC expression via de-ubiquitination of TRRAP.
Bhattacharya S; Ghosh MK
Cell Oncol (Dordr); 2015 Aug; 38(4):265-77. PubMed ID: 25925205
[TBL] [Abstract][Full Text] [Related]
14. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins.
McMahon SB; Van Buskirk HA; Dugan KA; Copeland TD; Cole MD
Cell; 1998 Aug; 94(3):363-74. PubMed ID: 9708738
[TBL] [Abstract][Full Text] [Related]
15. Chromosomal location targets different MYC family gene members for oncogenic translocations.
Gostissa M; Ranganath S; Bianco JM; Alt FW
Proc Natl Acad Sci U S A; 2009 Feb; 106(7):2265-70. PubMed ID: 19174520
[TBL] [Abstract][Full Text] [Related]
16. MYC in oncogenesis and as a target for cancer therapies.
Albihn A; Johnsen JI; Henriksson MA
Adv Cancer Res; 2010; 107():163-224. PubMed ID: 20399964
[TBL] [Abstract][Full Text] [Related]
17. MYC Analysis in Cancer and Evolution.
Hartl M; Bister K
Methods Mol Biol; 2021; 2318():87-117. PubMed ID: 34019288
[TBL] [Abstract][Full Text] [Related]
18. A druggable conformational switch in the c-MYC transactivation domain.
Lama D; Vosselman T; Sahin C; Liaño-Pons J; Cerrato CP; Nilsson L; Teilum K; Lane DP; Landreh M; Arsenian Henriksson M
Nat Commun; 2024 Feb; 15(1):1865. PubMed ID: 38424045
[TBL] [Abstract][Full Text] [Related]
19. MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer.
Stefan E; Bister K
Curr Top Microbiol Immunol; 2017; 407():117-151. PubMed ID: 28466200
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of N-Myc and c-Myc synthesis, degradation, and transcriptional activity by the Ras/mitogen-activated protein kinase pathway.
Kapeli K; Hurlin PJ
J Biol Chem; 2011 Nov; 286(44):38498-38508. PubMed ID: 21908617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
